http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2138512-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07154cfa9a1fe9901ceeaca89c58550d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-102 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 1990-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1999-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6522d88acb345580bbaf5684d54fb9cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0123c8092ee268024c0da03c5c219a1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da448494cae9e991fbcb34cb32925234 |
| publicationDate | 1999-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2138512-C1 |
| titleOfInvention | Vaccine for prophylaxis and treatment of t-cells mediated pathology or nonregulated replication by t-cell clones, method of isolation of vaccine, method of diagnosis or prognosis of susceptibility to rheumatoid arthritis of cerebrospinal sclerosis, method of prophylaxis or treatment of patients with rheumatoid arthritis or cerebrospinal sclerosis and peptide containing sequence sgdqggne as agent for detection, prophylaxis and treatment of patients with cerebrospinal sclerosis |
| abstract | FIELD: medicine, immunology. SUBSTANCE: invention proposes a vaccine for prophylaxis and treatment of patients with T-cells mediated pathology or nonregulated replication of mammals T-cells that contains an active substance and pharmaceutically tolerantable medium. It has receptor of T-cells or its fragment corresponding to T-cells receptor as an active substance and located on surface mediating this pathology or anti-idiotypic antibodies that are an internal image of this receptor or its mentioned fragment. An active substance is taken at immunogenic effective amount. Vaccine is prepared by preparing T-cell clones causing T-cells mediated pathology and involves the determination of amino acid sequence of receptors of T-cells of clones of T-cells associated with this pathology, selection of fragments of these T-cell receptors which are typical for mentioned receptors of T-cells rather then for receptors of T-cells not associated with this pathology. Then method involves the selection of nonmentioned sequences that are able to induction of immunogenic response with respect to mentioned T-cells receptors that results to the vaccine selection. Also, invention proposes a method of diagnosis or prognosis of the person susceptibility to rheumatoid arthritis that involves the detection of T-cells containing variable site of β-strand: MSNQVLCCVVLCFLGANTVDGGITQSPKYLFRKQNVTLSCEQNLNDAMYWYRQDPGQGLRL- -IYYSQIVNDFQKGDIAEGYSVSREKKESFPLTVTSAQKNPTAFYLCASS or its fragment in the person sample. Anomalous expression of T-cells containing this site indicates the presence of rheumatoid arthritis or susceptibility to rheumatoid arthritis and a method of prophylaxis and treatment of patients with rheumatoid arthritis. Method involves the prevention of binding T-cells receptor containing the sequence: MSNQVLCCVVLCFLGANTVDGGITQSP- -KYLFRKEGQNVTLSCEQNLNHDAMYWYRQDPGQGLRLLIYYSQIVNDFQKGDIAEGYSVS- -REKKESFPLTVTSAQKNPTAFYLCASS or T-cells receptor containing mainly the sequence SGDQGGNE with its partner and a method of prophylaxis and treatment of patients with rheumatoid arthritis. Method involves cytotoxic or cytostatic treatment of T-cells, the sequence MSNQVLCCVVLCFLGANTVDGGITQSPKYLFRKEGQNVTLSCEQNLNH- -DAMYWYRQDPGQGLRLIYYSQIVNDFQKGDIAEGYSVSPEKKESFPLTVTSAQKNPTAFY- -CASS or T-cells containing mainly the sequence SGDGGNE in the person. EFFECT: vaccine indicated above, improved method of prophylaxis and treatment, active peptide. 21 cl, 10 tbl, 9 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2563360-C2 |
| priorityDate | 1989-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 87.